Evidence map›Paper›PMID 35795052›Full record

ArticleFrontiers in oncology2022

The Risk of Heart Disease-Related Death Among Anaplastic Astrocytoma Patients After Chemotherapy: A SEER Population-Based Analysis.

Qi Lin, Jia-Hao Bao, Fei Xue, Jia-Jun Qin, Zhen Chen, Zhong-Rong Chen, Chao Li, Yi-Xuan Yan, Jin Fu, Zhao-Li Shen and 1 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Qi LinDepartment of Neurosurgery, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Jia-Hao BaoHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, China.
Fei XueDepartment of Neurosurgery, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Jia-Jun QinDepartment of Neurosurgery, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Zhen ChenDepartment of Neurosurgery, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Zhong-Rong ChenDepartment of Neurosurgery, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Chao LiDepartment of Neurosurgery, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Yi-Xuan YanHospital of Stomatology, Guanghua School of Stomatology, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, China.
Jin FuDepartment of Neurosurgery, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Zhao-Li ShenDepartment of Neurosurgery, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Xian-Zhen ChenDepartment of Neurosurgery, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Tongji University · CNStomatology Hospital · CNShanghai Tenth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite improved overall survival outcomes, chemotherapy has brought concerns for heart disease-related death (HDRD) among cancer patients. The effect of chemotherapy on the risk of HDRD in anaplastic astrocytoma (AA) patients remains unclear. Methods: We obtained 7,129 AA patients from the Surveillance, Epidemiology, and End Results (SEER) database from 1975 to 2016. Kaplan-Meier and Cox regression analysis were conducted to evaluate the effect of chemotherapy on the HDRD risk. Based on the competing risk model, we calculated the cumulative incidences of HDRD and non-HDRD and performed univariate and multivariate regression analyses. Then, a 1:1 propensity score matching (PSM) was used to improve the comparability between AA patients with and without chemotherapy. Landmark analysis at 216 and 314 months was employed to minimize immortal time bias. Results: AA patients with chemotherapy were at a lower HDRD risk compared to those patients without chemotherapy (adjusted HR=0.782, 95%CI=0.736-0.83, Conclusion: AA patients with chemotherapy are associated with a lower risk of HDRD compared with those without chemotherapy. Our findings may help clinicians make a decision about the management of AA patients and provide new and important evidence for applying chemotherapy in AA patients as the first-line treatment. However, more research is needed to confirm these findings and investigate the correlation of the risk of HDRD with different chemotherapy drugs and doses.

Indexed as

anaplastic astrocytomacardio-oncologychemotherapyheart disease-related deathSEER

Identifiers

PMID35795052
PMCPMC9251342
OpenAlexW4283159372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.